Triglav Skladi D.O.O. Makes New $7.90 Million Investment in CVS Health Co. (NYSE:CVS)

Triglav Skladi D.O.O. purchased a new stake in CVS Health Co. (NYSE:CVS) during the 4th quarter, HoldingsChannel reports. The firm purchased 176,080 shares of the pharmacy operator’s stock, valued at approximately $7,904,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in CVS. Stonebridge Financial Group LLC acquired a new stake in shares of CVS Health in the fourth quarter valued at about $28,000. Hopwood Financial Services Inc. acquired a new stake in shares of CVS Health in the fourth quarter valued at about $29,000. Financial Perspectives Inc grew its position in shares of CVS Health by 137.5% in the fourth quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator’s stock valued at $36,000 after purchasing an additional 466 shares during the last quarter. MidAtlantic Capital Management Inc. grew its position in shares of CVS Health by 112.1% in the fourth quarter. MidAtlantic Capital Management Inc. now owns 827 shares of the pharmacy operator’s stock valued at $37,000 after purchasing an additional 437 shares during the last quarter. Finally, Compass Planning Associates Inc acquired a new stake in shares of CVS Health in the fourth quarter valued at about $37,000. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Stock Up 3.4%

Shares of CVS opened at $62.51 on Monday. The stock has a market cap of $79.07 billion, a price-to-earnings ratio of 17.08, a P/E/G ratio of 0.98 and a beta of 0.60. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. CVS Health Co. has a 12 month low of $43.56 and a 12 month high of $72.51. The company has a 50-day moving average price of $66.57 and a two-hundred day moving average price of $59.24.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.63. The firm had revenue of $94.59 billion during the quarter, compared to analysts’ expectations of $93.07 billion. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.31 earnings per share. Equities analysts predict that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd were issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 4.26%. The ex-dividend date of this dividend was Tuesday, April 22nd. CVS Health’s payout ratio is 63.48%.

Analyst Ratings Changes

CVS has been the topic of several research analyst reports. Cowen reaffirmed a “buy” rating on shares of CVS Health in a research report on Monday, May 5th. Edward Jones upgraded shares of CVS Health from a “hold” rating to a “buy” rating in a research note on Thursday, January 30th. Leerink Partners upgraded shares of CVS Health from a “market perform” rating to an “outperform” rating and increased their target price for the company from $55.00 to $75.00 in a research note on Thursday, February 13th. Robert W. Baird increased their target price on shares of CVS Health from $51.00 to $71.00 and gave the company a “neutral” rating in a research note on Tuesday, April 15th. Finally, Argus set a $77.00 target price on shares of CVS Health in a research note on Tuesday, February 18th. Three equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $74.94.

Insider Transactions at CVS Health

In related news, SVP James David Clark sold 7,513 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the sale, the senior vice president now owns 8,394 shares of the company’s stock, valued at $556,941.90. This trade represents a 47.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Michael F. Mahoney purchased 30,000 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was bought at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the acquisition, the director now owns 39,356 shares of the company’s stock, valued at $2,625,045.20. This represents a 320.65% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.22% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.